Floatz logo

asp3026

Solid Tumor

Astellas Pharma IncPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

928 Active assets in the Solid Tumor cohort.

View all 50

Same molecule, other indications

asp3026 is also rated in:

cancerDormant
CC
Indicative ·
46 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
42 / 100
View asset →
ALK-positive anaplastic large cell lymphomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →